Literature DB >> 9412303

Reversibility of hepatic fibrosis in autoimmune hepatitis.

J F Dufour1, R DeLellis, M M Kaplan.   

Abstract

BACKGROUND: Hepatic fibrosis and cirrhosis occur in many types of chronic liver injury and generally seem to be irreversible.
OBJECTIVE: To determine whether cirrhosis caused by autoimmune hepatitis can be reversible.
DESIGN: Retrospective study. PATIENTS: Eight patients with autoimmune hepatitis and cirrhosis who responded to medical therapy and had follow-up liver biopsy while in clinical and biochemical remission. MEASUREMENTS: Biopsy specimens were randomly coded in an unpaired manner according to patient and were read independently by two pathologists using the Knodell scoring system.
RESULTS: The median alanine aminotransferase level decreased from 10.30 mukat/L to 0.37 mukat/L, the median serum bilirubin level decreased from 70 mumol/L to 10 mumol/L, and the median serum albumin level increased from 34 g/L to 43 g/L. Cirrhosis, extensive fibrosis, or both were present in all patients at diagnosis but were not present on follow-up liver biopsy. The median Knodell score decreased from 14.0 to 1.3, and the median fibrosis score decreased from 3.3 to 0.8.
CONCLUSION: Hepatic fibrosis and cirrhosis may be reversible in some patients in whom autoimmune hepatitis responds to treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9412303     DOI: 10.7326/0003-4819-127-11-199712010-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  68 in total

Review 1.  Is liver fibrosis reversible?

Authors:  R C Benyon; J P Iredale
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

Review 2.  Targeting Hepatic Fibrosis in Autoimmune Hepatitis.

Authors:  Aldo J Montano-Loza; Ragesh B Thandassery; Albert J Czaja
Journal:  Dig Dis Sci       Date:  2016-07-19       Impact factor: 3.199

3.  Current status of therapy in autoimmune liver disease.

Authors:  Gideon M Hirschfield; Nadya Al-Harthi; E Jenny Heathcote
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

Review 4.  An appraisal of the histopathological assessment of liver fibrosis.

Authors:  R A Standish; E Cholongitas; A Dhillon; A K Burroughs; A P Dhillon
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

Review 5.  Current and future anti-fibrotic therapies for chronic liver disease.

Authors:  Don C Rockey
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

6.  Clinical and Pathological Risk Factors Associated with Liver Fibrosis and Steatosis in African-Americans with Chronic Hepatitis C.

Authors:  Ali Afsari; Edward Lee; Babak Shokrani; Tina Boortalary; Zaki A Sherif; Mehdi Nouraie; Adeyinka O Laiyemo; Kawtar Alkhalloufi; Hassan Brim; Hassan Ashktorab
Journal:  Dig Dis Sci       Date:  2017-06-13       Impact factor: 3.199

7.  Evaluation of risk factors for the development of cirrhosis in autoimmune hepatitis: Japanese NHO-AIH prospective study.

Authors:  Kiyoshi Migita; Yukio Watanabe; Yuka Jiuchi; Yoko Nakamura; Akira Saito; Michiyasu Yagura; Hideo Morimoto; Masaaki Shimada; Eiji Mita; Taizo Hijioka; Haruhiro Yamashita; Eiichi Takezaki; Toyokichi Muro; Hironori Sakai; Makoto Nakamuta; Seigo Abiru; Koji Yano; Atsumasa Komori; Hiroshi Yatsuhashi; Minoru Nakamura; Hiromi Ishibashi
Journal:  J Gastroenterol       Date:  2010-11-02       Impact factor: 7.527

8.  Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis.

Authors:  Mehdi Mohamadnejad; Reza Malekzadeh; Siavosh Nasseri-Moghaddam; Sepideh Hagh-Azali; Nasser Rakhshani; Seyed Mohamad Tavangar; Mojtaba Sedaghat; Seyed Meysam Alimohamadi
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

Review 9.  Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2010-01-27       Impact factor: 3.199

Review 10.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.